YOKOHAMA, Japan--(BUSINESS WIRE)--Sep. 16, 2013-- At the 12thHUPO World Congress, Bruker Corporation (NASDAQ: BRKR) today announced the start of a second-phase collaboration agreement with SISCAPA Assays Technologies, Inc. (SAT). The ongoing collaboration aims to exploit the high throughput, robustness and ease of use of MALDI-TOF instruments as an alternative to nano-LC-MS technology currently used in many SISCAPA assays.
布鲁克（Bruker）和萨特（SAT）的第一阶段合作导致了两个出版物。第一篇论文发表在Journal of Proteome Research,demonstrated that a SISCAPA-MALDI workflow showed quantitative precision equal to or better than SISCAPA LC-MS/MS workflows, with the improved ease of use that comes from eliminating the need for LC and MS/MS. The second paper, published in the journalClinical Chemistry, validated the quantitative precision for a larger cohort of samples of clinical relevance, measuring the endogenous levels of Protein C Inhibitor from serum samples of patients who had been treated for prostate cancer. A summary of this work will be presented in a poster at the 12thHumanProteome Organization World Congress (HUPO).
在确认了Siscapa-Maldi工作流程的实用性和定量精度之后，第二相协作将集中于涉及临床上有用的生物标志物测量的许多进一步发展。所有Siscapa-Maldi分析目前仅用于研究用途，而不是用于诊断程序。
Bruker plans to establish fully automated SISCAPA-MALDI capabilities in its demonstration facilities, allowing interested customers to evaluate SISCAPA-MALDI instrumentation and workflows. The demo facility will also enable high-level applications and service support for such customers by Bruker personnel.
Assay Development:Additional SISCAPA assays will be validated and parameters, such as the limit of quantitation and limit of detection (LOQ/LOD), will be determined. Bruker and SAT also plan to enable third-party collaborators to develop SISCAPA-MALDI assays for accurate quantification of their own protein targets, for use in RUO and clinical research environments. Such assays would be useful for a diverse range of customers, e.g. those wishing to pursue protein quantitation for process optimization or large-scale clinical validation of protein biomarkers. Bruker and SAT also jointly plan to investigate the development of new assays for the SISCAPA-MALDI workflow. Of particular interest are assays of relevance to clinical microbiology, as the previous work has shown that such assays could be run on the benchtopmicroflex LT, the same mass spectrometer employed in theBrukerMALDI BIOTYPER. Successful validation and clearance for clinical use of such assays would immediately make them available to the more than 900 (and growing) clinical microbiology laboratories worldwide that already have aMALDI BIOTYPERinstalled.
SAT的首席执行官兼创始人Leigh Anderson博士，Siscapa的发明者，并评论说：“我们很高兴与MALDI-TOF Technology的领导者Bruker合作，以提高Siscapa Biomarker Assays的精确度和吞吐量我们的联合论文证明了使用内部标准的MALDI-TOF质谱法进行肽定量的高度，并为进一步探索Siscapa-Maldi-Tof MS在生物标志物验证和临床前研究中的实用性建立了坚实的基础。为了开发和应用Siscapa分析，我们很高兴布鲁克（Bruker）投资将Siscapa-Maldi的工作流程带入其示范设施，这将使用Siscapa提高实验室的生产率，并促使采用Siscapa测定法生物标志物研究界。”
Dr. Detlev Suckau, Director of Proteomics at Bruker Daltonics, added: "The results of the joint work prove that MALDI-TOF is very suitable for peptide and protein quantification in the one- to five-percent CV range, and also for the validation of protein biomarkers in clinical research. With the early phase of this research completed, Bruker has the confidence in SAT and SISCAPA-MALDI MS to make a significant investment needed to bring the fully automated SISCAPA-MALDI MS workflow into our demonstration facilities. This will enable Bruker, in partnership with SAT, to sell SISCAPA-MALDI MS to customers and to support the many enthusiastic early adopters who have expressed interest in this technology."
About SISCAPA Assay Technologies, Inc.
SISCAPA Assay Technologies (SAT) is focused on creating SISCAPA® assays for a growing menu of high-value protein biomarkers, with the long-term goal of enabling sensitive, precise, high-throughput measurement of every human protein of clinical significance. Additional information about SISCAPA affinity-MS technology, available reagents, and licensing opportunities is available atwww.SISCAPA.com.
About Bruker Corporation
Bruker Corporation（NASDAQ：BRKR）是用于分子和材料研究以及诊断，工业和应用分析的高性能科学工具和解决方案的领先提供商。bob娱乐平台bob综合游戏有关更多信息，请访问www.energie2point0.com
Photos/Multimedia Gallery Available:http://www.businesswire.com/multimedia/home/20130916005210/en/
Source: Bruker Corporation
Bruker Daltonics, Inc.
Gary Kruppa, Ph. D., +1-978-663-3660, ext. 1227
Vice President of Business Development
[电子邮件保护]